Vimarsana
Biggest News Aggregation in the World

Issue Supplement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Issue Supplement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Issue Supplement Today - Breaking & Trending Today

Health Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis - Vimarsana News

Health Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Approval is based on results from three Phase 3 studies: two for induction and one for maintenance 1,2,3In clinical trials, patients taking RINVOQ achieved the primary endpoint of clinical remission ...

Real estate markets, financial stability and macroprudential policy - Vimarsana News

Real estate markets, financial stability and macroprudential policy

The European Central Bank (ECB) is the central bank of the 19 European Union countries which have adopted the euro. Our main task is to maintain price stability in the euro area and so preserve the purchasing power of the single currency.

Frozen embryo transfers linked with risk of high BP during pregnancy - Vimarsana News

Frozen embryo transfers linked with risk of high BP during pregnancy

Frozen embryo transfers are now increasingly common all over the world as IVF technique compared to fresh embryo transfer.According to a new study Frozen embryo transfers during IVF were linked to...

The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Ulcerative Colitis - Vimarsana News

The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Ulcerative Colitis

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced The Lancet published results from three pivotal Phase 3 clinical trials – U-ACHIEVE (induction),...